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The NO/cGMP signal transduction is involved in the reg-
ulation of a variety of physiological processes e.g. smooth
muscle relaxation and platelet aggregation. As signalling
molecule, NO has diverse effects with NO-sensitive guan-
ylyl cyclase (NO-GC) being accepted as the most impor-
tant NO receptor. To differentiate between cGMP-
dependent and -independent effects of NO inhibitors for
the NO-GC are broadly used. The commonly used inhib-
itor for NO-GC is ODQ (1H-[1,2,4]Oxadiazolo[4,3-
a]quinoxalin-1-one). The precise mechanism of NO-GC
inhibition by ODQ remains unclear.
Recently, we have generated mice deficient in NO-GC
(GC-KO). GC-KO mice show a pronounced increase in
blood pressure, underlining the importance of NO in the
regulation of smooth muscle tone in vivo. We showed a
total lack of NO affecting smooth muscle tone and plate-
let aggregation which confirms NO-GC as the only NO
target regulating these two functions in mice.
Using these KO mice we can evaluate the specificity of
ODQ as inhibitor of NO-GC. In fact, ODQ used at low
μM concentrations is a good inhibitor of cGMP signalling,
allowing its use to investigate the cGMP dependence of
NO effects. However, high NO concentrations elicited
relaxation responses in ODQ-treated WT smooth muscle
via NO-GC as they were absent in GC-KO tissue. This
shows that NO-induced effects in the presence of ODQ do
not necessarily indicate cGMP independence.
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